

Expanded View Figures




Figure EV1. Slc1a3 is expressed in ORS, SG, and IFE stem cell niches but not in the telogen hair follicle.

- A Slc1a3 is not expressed in hair follicle stem cells in telogen.
- B Slc1a3 and Slc1a3-CreER^{T2} expression overlap. YFP expression is restricted to Slc1a3-CreER^{T2} cells immediately after recombination.
- C Slc1a3-CreER^{T2} is expressed in the Sox9⁺ ORS and absent from the matrix and inner layers of the growing hair follicle.
- D, E Slc1a3 is robustly expressed in a fraction of K5⁺/K5^{low}FABP5⁻ SG basal cells and a few K5⁺FABP5^{low} SG cells.
- F, G In the IFE, Slc1a3 is expressed in a subset of K5⁺ basal and all Loricrin⁺ suprabasal cells.

Data information: Dashed lines outline bulge (A) and SG (D, E) and indicate epidermal–dermal border (F, G). Continuous lines outline dermal papilla. Scale bars = 20 μm.




Figure EV2. Slc1a3 deletion does not alter the number of hair follicles and hair anchoring.

A-C Hair follicle density (A, B) and CD34 and K6 stem cell niche marker expression (C) of P24 Slc1a3^{+/+} animals ($n = 4$, 1,6 mm² skin per animal) compared to Slc1a3^{-/-} littermates ($n = 4$, 1,6 mm² skin per animal).

D Tile scan micrographs of back skin indicating pigmented regions in which hair follicles are in anagen of 3-month-old Slc1a3^{+/+} and Slc1a3^{-/-} animals.

E Hair shaft density of 3-month-old Slc1a3^{+/+} ($n = 4$, 355 HFfs) compared to Slc1a3^{-/-} ($n = 4$, 391 HFfs) animals.

F Comparison of hair follicle density of aged Slc1a3^{+/+} ($n = 4$, 1,6 mm² skin per animal) and Slc1a3^{-/-} animals ($n = 4$, 1,6 mm² skin per animal).

G Plucked hair shafts of Slc1a3^{+/+} and Slc1a3^{-/-} mice show no difference in the amount of attached K6+ inner bulge cells.

Data information: Data are mean \pm SEM; n.s. = not significant (two-tailed Student's t-test in B and F, Mann-Whitney U-test in E). Scale bars = 20 μ m except in (A), scale bar = 30 μ m.

Source data are available online for this figure.




Figure EV3. Slc1a3 is transiently expressed in SG basal cells, which can self-maintain SGs for at least 8 months.

A Recombination induction during telogen (P51-55) labels cells in the sebaceous gland (SG) but not in the hair follicle.
 B, C The Slc1a3-CreER^{T2} mouse line does not target cells in the isthmus or around the SG orifice and these regions neither contain YFP⁺ cells 5 days after recombination induction (B) nor express Slc1a3-CreER^{T2} (C), excluding contribution of YFP⁺ SG cells from these regions.
 D Sections of lineage-traced dorsal back skin directly (P55) or 8 months (8 mo) after 5 consecutive days of tamoxifen injection. Over time, the number of YFP⁺ cells in YFP⁺ SGs increases while the number of YFP⁺ SGs decreases. FABP5⁺ sebocytes in red mark SGs, and asterisks indicate SGs containing YFP⁺ cells.
 E Following lineage tracing, YFP⁻ SGs contain CreER^{T2}⁺Slc1a3⁺ basal cells.
 Data information: Dashed lines outline the SG. Scale bars = 20 μm except in (D) scale bar = 100 μm.




Figure EV4. Slc1a3 is transiently expressed in active cycling SG and IFE cells.

A Percentage of YFP⁺ SGs after 2 ($n = 4$, 200 SGs) compared to 5 ($n = 4$, 200 SGs) consecutive days of tamoxifen injection, assessed at the same time during telogen.
 B Number of YFP⁺ cell clusters in 10 mm IFE after 2 ($n = 4$, 40 mm) compared to 5 ($n = 3$, 30 mm) consecutive days of tamoxifen injection, assessed at the same time during telogen.
 C Schematic depiction of the genetic strategy to block proliferation of Slc1a3⁺ cells, by tamoxifen inducible cell-specific deletion of all Ras genes.
 D, E Representative micrographs showing proliferating (Ki67⁺) cells in SG (D) and IFE (E) after recombination-mediated block of proliferation in Slc1a3⁺ cells (Slc1a3-CreER^{T2}⁺) compared to control (Slc1a3-CreER^{T2}⁻) animals.

Data information: Data are mean ± SEM; * $P < 0.05$ (two-tailed Student's t -test). Dashed lines outline the SG (B) and indicate the epidermal–dermal border (C). Scale bar = 20 μm.
 Source data are available online for this figure.




Figure EV5. Slc1a3 and mGluR5 act together.

- A Quantification of hair cycle progression assessed by hair follicle staging following topical treatment with mGluR5 antagonist MTEP ($n = 4, 120$ HF) or vehicle ($n = 4, 120$ HF) in *Slc1a3^{-/-}* mice. P -value derived from grouped comparison of ranked HF stages in mice treated with vehicle and MTEP.
- B Quantification of hair cycle progression assessed by hair follicle staging following cutaneous treatment with L-glutamate (L-Glu; $n = 5, 75$ HF) in comparison with vehicle-treated mice ($n = 3, 48$ HF). P -value derived from grouped comparison of ranked HF stages in mice treated with vehicle and L-Glu.
- C–F Quantification of proliferation (C, E) and growth (D, F) of SG (C, D) and IFE (E, F) following topical treatment with MTEP ($n = 4, 79$ SGs and 7 mm IFE, respectively) or vehicle ($n = 4, 77$ SGs and 8 mm IFE, respectively) in *Slc1a3^{-/-}* mice.
- G–J Quantification of proliferation (G, I) and size (H, J) of SG (G, H) and IFE (I, J) following cutaneous treatment with L-glutamate ($n = 4, 46$ and 48 SGs, 5 mm, respectively) compared to vehicle ($n = 3, 32$ and 22 SGs, 3 mm, respectively).

Data information: Data are mean \pm SEM in (A, B, E–H) and mean \pm SEM in (C and D); n.s. = not significant (Mann–Whitney U -test in A and B, two-tailed Student's t -test in C–J).
 Source data are available online for this figure.